Clinical Trials on Unresectable Lung Carcinoma in Canada

Total 5066 results

Shattuck Labs, Inc.

Completed

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Melanoma | Renal Cell Carcinoma | Hodgkin Lymphoma | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Diffuse Large B Cell Lymphoma | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Squamous Cell Carcinoma of the Skin | Squamous Cell Carcinoma... and other conditions

United States, Canada, Belgium, Spain
Seagen Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SEA-CD40 Given With Other Drugs in Cancers

Melanoma | Carcinoma, Non-Small- Cell Lung

United States, Canada, Spain, France, Germany, Sweden
Association of Dermatological Prevention, Germany
University of Alberta; University of Calgary

Unknown

Skin Cancer Screening Education Study (SCSES)

Melanoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Skin Tumors

Canada
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Fundación GECP

Completed

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (OSIREX)

Non Small Cell Lung Cancer

Spain
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada
Lawson Health Research Institute

Completed

A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy

Renal Cell Carcinoma

Canada
St. Joseph's Healthcare Hamilton
Novartis Pharmaceuticals; McMaster University

Completed

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Carcinoma, Renal Cell

Canada
St. Joseph's Healthcare Hamilton
Pfizer; McMaster University

Completed

Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Canada
AnHeart Therapeutics Inc.

Recruiting

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)

Non Small Cell Lung Cancer

United States, Spain, France, Italy, Japan, Korea, Republic of, Canada, China, Poland
Lawson Health Research Institute

Recruiting

Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer (SAVIOR)

Hepatocellular Carcinoma | Liver Metastases

Canada
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Canada, Italy, Poland, Turkey, Sweden, Switzerland
University Health Network, Toronto
Pfizer

Completed

Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma (AXITINIB)

Hepatocellular Carcinoma

Canada
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, Brazil, Korea, Republic of, Spain, Argentina, United States, Costa Rica, Chile, Latvia, Finland, Italy, Poland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States, France, Germany, Spain, Belgium, Poland, Canada, Hungary, Italy, Czechia
National Cancer Institute (NCI)

Active, not recruiting

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC... and other conditions

United States, Canada
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
Theratechnologies
PPD; Syneos Health; Windtree Therapeutics; Innovaderm Research Inc.; Altasciences...

Recruiting

TH1902 in Patients With Advanced Solid Tumors

Solid Tumor | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Small-cell Lung Cancer | Thyroid Cancer | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer | Hormone Receptor-positive Breast Cancer | SORT1+ Cancers

United States, Canada
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Seagen Inc.

Recruiting

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Canada, Belgium, Spain, France, Poland, Germany, Italy, Greece, Norway, Hungary, Czechia, Netherlands, Romania
Pfizer

Terminated

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Adenosquamous | Carcinoma, Large Cell

United States, Bulgaria, Canada, Ukraine, Greece, Austria, France, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, Finland, Hungary, Taiwan, Italy, Japan, Australia, Germany, Brazil, India, Puerto Rico, Czech Republic, ... and more
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Lung Cancer

United States, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, Croatia, Taiwan, Greece, Canada, Thailand, Lebanon, Australia, Hong Kong, Slovenia, Spain, Jordan, Korea, Republic of, Romania, Italy, Hungary, India, Turkey, Portugal, Argentina, Malaysia, Colombia, Iceland, Vietnam, Mexico, United... and more
Eli Lilly and Company

Completed

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Poland, Belgium, Canada, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Carcinoma, Non-Small-Cell Lung

United States, Ireland, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom
NCIC Clinical Trials Group

Completed

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer

United States, Spain, Canada, Italy, France, Switzerland, Netherlands, Belgium, Germany, Finland, United Kingdom, Poland, Portugal, Austria
Genta Incorporated
National Cancer Institute (NCI)

Unknown

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Russian Federation
Wako Life Sciences

Unknown

A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers

Cirrhosis | Chronic Liver Diseases

Canada
Bristol-Myers Squibb

Recruiting

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

Netherlands, Belgium, United States, Australia, Greece, Italy, Canada, Japan, Poland, Romania, Spain
Hoffmann-La Roche

Completed

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, Belgium, Turkey, United Kingdom, Germany, Poland, Canada, France, Thailand, Italy, Sweden
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
MedImmune LLC

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

Unresectable Pleural or Peritoneal Malignant Mesothelioma

United States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Advanced Cancer

United States, Spain, France, Austria, Italy, Australia, Canada, Switzerland
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Angiochem Inc

Terminated

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) (GRABM-L)

Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

United States, Canada
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

United States, Canada, Netherlands, Belgium, Israel, Spain, France, Italy
Sunnybrook Health Sciences Centre
Celgene Corporation

Completed

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Transitional Cell Carcinoma

Canada
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Regeneron Pharmaceuticals

Recruiting

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States, Israel, Malaysia, Australia, Georgia, Turkey, Canada
University Health Network, Toronto

Active, not recruiting

Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation (PETMRIinHCC)

Hepatocellular Carcinoma

Canada
Boehringer Ingelheim

Completed

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, Thailand, United Kingdom
Revolution Medicines, Inc.
Sanofi; Amgen

Active, not recruiting

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Spain, United Kingdom, Italy, Australia, France, Germany
AbbVie

Withdrawn

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia, Brazil, Canada, Germany, Sweden, United Kingdom

Clinical Trials on Unresectable Lung Carcinoma in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations